Department of Radiotherapy, University Medical Center Utrecht, The Netherlands.
Department of Radiotherapy, University Medical Center Utrecht, The Netherlands.
Eur J Surg Oncol. 2018 Jul;44(7):1013-1017. doi: 10.1016/j.ejso.2018.03.014. Epub 2018 Mar 23.
Patients with locally advanced rectal cancer (LARC) who are unfit for chemoradiation (CRT), are often offered short-course radiotherapy followed by delayed surgery (SCRT-delay). This entails a lower radiation dose, no chemotherapy and a shorter treatment period. This may lower their chances for complete tumor response and, as such, organ-sparing approaches. The purpose of this study was to compare the pathological complete response (pCR) rates between neoadjuvant CRT and SCRT-delay in patients with LARC in a nationwide database from the Netherlands.
In the population based Netherlands Cancer Registry, clinical stage III rectal cancer patients, diagnosed between 2008 and 2014, who underwent CRT or SCTR-delay were selected. pCR (ypT0N0), near pCR (ypT0-1N0), and tumor and nodal downstaging were compared between the treatment groups using multivariable logistic regression analysis.
386 patients underwent SCRT-delay and 3659 patients underwent CRT. The pCR-rate in the SCRT-delay group was significantly lower compared to the CRT-group (6.4% vs. 16.2%, p < 0.001). After adjustment for clinical tumor stage, clinical nodal stage and time interval to surgery, SCRT-delay patients were significantly less likely to reach pCR (adjusted odds ratio 0.3, 95%CI 0.2-0.5). Also, near-pCR (ypT0-1N0) as well as tumor and nodal downstaging was observed less often in the SCRT-delay group.
Compared to patients treated with neoadjuvant CRT, those receiving SCRT and delayed surgery are less likely to develop pCR. Novel neoadjuvant treatment strategies for patients not fit enough for CRT are needed to increase their eligibility for organ-sparing treatments.
不适合放化疗(CRT)的局部晚期直肠癌(LARC)患者,通常会接受短程放疗加延期手术(SCRT-delay)。这种治疗方法的放射剂量较低,不进行化疗,且治疗时间较短。这可能会降低他们完全肿瘤反应的机会,从而降低保留器官的治疗方法的适用率。本研究的目的是在荷兰全国数据库中,比较新辅助 CRT 和 SCRT-delay 治疗 LARC 患者的病理完全缓解(pCR)率。
在基于人群的荷兰癌症登记处中,选择了 2008 年至 2014 年间诊断为临床 III 期直肠癌且接受 CRT 或 SCRT-delay 的患者。使用多变量逻辑回归分析比较两组患者的 pCR(ypT0N0)、接近 pCR(ypT0-1N0)、肿瘤和淋巴结降级情况。
386 例患者接受 SCRT-delay,3659 例患者接受 CRT。SCRT-delay 组的 pCR 率明显低于 CRT 组(6.4% vs. 16.2%,p<0.001)。调整临床肿瘤分期、临床淋巴结分期和手术间隔时间后,SCRT-delay 组患者达到 pCR 的可能性显著降低(调整后的优势比 0.3,95%CI 0.2-0.5)。此外,SCRT-delay 组患者接近 pCR(ypT0-1N0)和肿瘤及淋巴结降级的情况也较少。
与接受新辅助 CRT 治疗的患者相比,接受 SCRT 和延期手术的患者发生 pCR 的可能性较低。需要为不适合 CRT 的患者制定新的新辅助治疗策略,以提高其接受保留器官治疗的可能性。